Physician profile

David Irwin Jones

Critical Care Medicine (Internal Medicine) · Tyler, TX

NPI 1366440596

$8,623.32

in general payments reported to CMS, 2019-2025

41 companies · $51.73 in 2025

The $51.73 reported for 2025 was less than what a typical Critical Care Medicine (Internal Medicine) provider received nationally (typical 2025 total: $189).

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$2,602.76
Education$99.99

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Glaxosmithkline, LLC. $1,322.43 2019-2024 Trelegy Ellipta, Nucala, Arexvy
Ethicon INC. $1,238.60 2019
Astrazeneca Pharmaceuticals LP $1,147.59 2019-2024 Tezspire, Airsupra, Bevespi Aerosphere
Mylan Specialty L.P. $529.44 2019-2024 Yupelri
Jazz Pharmaceuticals INC. $495.23 2019-2024
Boehringer Ingelheim Pharmaceuticals, INC. $467.72 2019-2024 Ofev
Harmony Biosciences LLC $436.91 2020-2024 Wakix
Intuitive Surgical, INC. $434.05 2021-2022
Actelion Pharmaceuticals US, INC. $425.31 2019-2024 Opsumit, Uptravi
Gilead Sciences, INC. $227.92 2019-2023
Baxter Healthcare $162.44 2022-2025 Hillrom - Vest System Model 105 Home Care, Hillrom - Life 2000 Ventilation System
Sunovion Pharmaceuticals INC. $147.24 2019
Inspire Medical Systems, INC. $140.92 2024 Inspire
United Therapeutics Corporation $131.01 2019-2024 Tyvaso
Pfizer INC. $130.81 2019-2023
Show all 41 companies
CompanyGeneral paymentsYearsTop products
Regeneron Healthcare Solutions, INC. $121.64 2023-2024 Dupixent
Axsome Therapeutics, INC. $114.54 2023-2024 Sunosi
Genzyme Corporation $105.99 2022-2024
Resmed Corp $86.36 2023
Salix Pharmaceuticals, A Division of Bausch Health US, LLC $78.16 2022-2023 Xifaxan
Advanced Respiratory, INC $77.82 2019-2020
Inogen, INC. $77.55 2023-2024 Inogen One G5 Oxygen Concentrator - Bluetooth
Ani Pharmaceuticals, INC. $76.24 2023-2024 Purified Cortrophin Gel
Csl Behring $60.79 2019-2024 Privigen, Hizentra
Genentech USA, INC. $47.27 2019-2022
Merck Sharp & Dohme LLC $39.19 2019
Abbvie INC. $34.91 2023-2024
Grifols USA, LLC $33.33 2024 Prolastin-C Liquid
Bayer Healthcare Pharmaceuticals INC. $32.06 2019
Ardelyx, INC. $24.79 2025 Ibsrela
Sanofi-Aventis U.S. LLC $22.35 2020
Mallinckrodt Hospital Products INC. $19.19 2024 Acthar
Novartis Pharmaceuticals Corporation $17.62 2019
Takeda Pharmaceuticals U.S.A., INC. $17.22 2024 Glassia
Electromed, INC. $16.87 2019
Hospira, INC. $16.86 2024
Fisher & Paykel Healthcare INC $15.43 2023 Fisher & Paykel Healthcare
Cmp Pharma, INC. $15.15 2023 Tadliq
Allergan, INC. $12.14 2020
Philips North America LLC $11.41 2019
Circassia INC. $10.82 2019

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

David Irwin Jones

$8,623.32

in general payments reported 2019-2025

Years
2019-2025
Top company
Glaxosmithkline, LLC.
Context
The $51.73 reported for 2025 was less than what a typical Critical Care Medicine (Internal Medicine) provider received nationally (typical 2025 total: $189).

https://glasscript.com/doctor/334294/david-irwin-jones

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.